Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Reuters NewMedia - November 18, 2004
Dr Diana Gibb, of Britain's Medical Research Council, and her colleagues said a trial involving HIV-infected children in Zambia was stopped early because it was so successful.
A daily dose of the drug co-trimoxazole nearly halved the death rate in youngsters taking it compared to those given a placebo.
"We believe that our results can be generalised to a policy that could be applied universally to children with clinical features of HIV infection in Africa and elsewhere," Gibb said.
She and her team, who reported the findings in The Lancet medical journal, said they believe all children should receive the drug, regardless of their age or CD4 count -- which measures immune system cells in the blood.
Children in the study were between 1 and 14-years-old.
HIV destroys the immune system and leaves the body vulnerable to a variety of life-threatening diseases, so-called opportunistic infections, such as tuberculosis or pneumonia.
"Co-trimoxazole in resource-limited settings where there are a lot of infections for children is certainly something that could have an impact on their quality of life, hospital admissions and mortality," Gibb said in an interview.
The researchers tested the drug in a trial of 541 children infected with HIV in Zambia. The youngsters were randomly selected to receive the treatment or a placebo and followed up for 19 months.
Twenty-eight percent of children in the drug group died, compared to 42 percent who had been given the placebo.
"Nutritional support and co-trimoxazole could definitely have an impact while waiting to see if anti-retrovirals can be rolled out," Gibb added. Anti-retrovirals are a class of drugs that are used to fight HIV/AIDS.
She said it would cost about $10 a year to provide co-trimoxazole for a child.
About 38 million adults and children worldwide are living with HIV, according UNAIDS, the Joint United Nations Programme on HIV/AIDS. The majority of cases are in sub-Saharan Africa.
Access to universal treatment is a major goal in the battle against the global epidemic.
041118
RE041137
Copyright © 2004 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .